Copenhagen Prospective Personalized Oncology (CoPPO)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUlrik Lassen
About this trial
Patients with advanced solid tumors referred to the Phase 1 Unit are offered mapping of GA for identification of pts who could benefit from a personalized treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Solid tumor
No standard treatment option
PS 0-1
Lesion assessable for biopsy
Disqualifiers
Life expectancy < 3 months
Bone marrow suppression
Abnormal renal or hepatic function
Serious concurrent medical conditions
Trial design
Design model
Single group
Treatments tested in this trial
Tumor biopsy
Procedure/SurgeryBiopsy of lesion for molecular characterization
Treatment groups
500 Participants
are divided into 1 treatment groupGroup A: tumor biopsyExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Median progression free survival (PFS)
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Time frame
Median time from date of randomization to date of progression or death, assessed up to 100 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Ulrik Lassen
Lead sponsor
Rigshospitalet, Denmark
Sponsor institution
Source ClinicalTrials.gov